Although aggressive tumors often express abnormally low amounts of the cell cycle inhibitor p27'^'''^ (p27), this is almost never due to mutation of the p27 gene. Although the data supporting the importance of p27 as a prognosfic indicator are strong, it is ultimately the relationship that we and others are defining between p27 and response to specific breast cancer therapies that will expand the clinical ufility of this single marker. It is sometimes assumed that p27 is a surrogate for proliferation and that it is not prognostic or predictive beyond its role in inhibiting the cell cycle. In this project, we will build on basic findings that confirm p27 funcfion is more complicated and that its regulafion and cellular localization mediate tumor progression and cellular responsiveness to therapies directed at breast cancer cells. We will begin the translafion of these basic discoveries by evaluating the relationship between clinical outcome and p27 expression and cellular localization in human breast cancers of women with at least five years of follow-up for breast cancer mortality. Compelling evidence indicates that the cellular localizafion of p27 could be an indicator of response to two important breast cancer therapies: anti-estrogen and anti-HER2. To characterize the effect of an anfi-estrogen and trastuzumab on expression and localizafion of p27, we will assay protein levels in samples pre- and post-administration of these agents. These relafively small human studies will guide the evaluation of p27 in larger clinical trials that have the power to assess the ability of this protein to predict response to therapy. In parallel we will be investigating a new pathway, involving TRIM62, that may be responsible, at least in part, for the cytoplasmic expression of p27 in HER2+ human breast cancers. We propose three aims:
Aim 1 will test the hypothesis that cytoplasmic p27 is a breast cancer oncogene affecting tumor initiation, invasion and metastasis.
Aim 2 will test the hypothesis that regulation of p27 by TRIM62, a new p27 regulator, plays an essential role in HER2-dependent oncogenic transformation.
Aim 3 will further test the hypothesis that increased cytoplasmic p27 is a prognosfic marker in human breast cancer, and ask whether cytoplasmic p27 predicts responsiveness to specific breast cancer therapeufics.

Public Health Relevance

Loss of p27 in tumor cells has been shown to be a marker of poor outcome for breast cancer. This project will test the possibility that cytoplasmic p27 expression predicts poor prognosis or response to anfi-estrogen and/or anfi-HER2 therapies. If it does, it will be possible to develop a method and assay that will not only be able to predict who will fail treatment, but will also allow us and others to gain insight into what targeted therapies are needed to treat resistant tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA138293-05
Application #
8728121
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
$226,500
Indirect Cost
$94,112
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Berger, Carolina; Sommermeyer, Daniel; Hudecek, Michael et al. (2015) Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 3:206-16
Stephan, Sirkka B; Taber, Alexandria M; Jileaeva, Ilona et al. (2015) Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33:97-101
Jensen, Michael C; Riddell, Stanley R (2014) Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 257:127-44
Marcondes, A Mario; Karoopongse, Ekapun; Lesnikova, Marina et al. (2014) ?-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood 124:2881-91
Partridge, Savannah C; Stone, Karen M; Strigel, Roberta M et al. (2014) Breast DCE-MRI: influence of postcontrast timing on automated lesion kinetics assessments and discrimination of benign and malignant lesions. Acad Radiol 21:1195-203
Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina et al. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20:141-4
Kennedy, Jacob J; Abbatiello, Susan E; Kim, Kyunggon et al. (2014) Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 11:149-55
Hudecek, Michael; Lupo-Stanghellini, Maria-Teresa; Kosasih, Paula L et al. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:3153-64
Sun, Jianping; Zheng, Yingye; Hsu, Li (2013) A unified mixed-effects model for rare-variant association in sequencing studies. Genet Epidemiol 37:334-44
Qu, Xiaoyu; Randhawa, Grace; Friedman, Cynthia et al. (2013) A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One 8:e74671

Showing the most recent 10 out of 14 publications